Bonus Biogroup (BONS) - Cash Flow Conversion Efficiency

Latest as of June 2025: 2.402x

Based on the latest financial reports, Bonus Biogroup (BONS) has a cash flow conversion efficiency ratio of 2.402x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-4.02 Million ≈ $-10.79K USD) by net assets (ILA-1.68 Million ≈ $-4.49K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bonus Biogroup - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Bonus Biogroup's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Bonus Biogroup for a breakdown of total debt and financial obligations.

Bonus Biogroup Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bonus Biogroup ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Marvipol S.A. WAR:MVP	-0.014x
ARRAIL GROUP LTD. F:I1D	N/A
John Hancock Income Securities Closed Fund NYSE:JHS	0.031x
AB Klaipedos nafta F:XIC	0.257x
Gevelot PA:ALGEV	0.028x
Bancroft Fund Limited NYSE MKT:BCV	-0.198x
Amotech Co. Ltd KQ:052710	0.021x
Prosafe SE OL:PRS	-0.021x

Annual Cash Flow Conversion Efficiency for Bonus Biogroup (2008–2024)

The table below shows the annual cash flow conversion efficiency of Bonus Biogroup from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Bonus Biogroup.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA6.96 Million ≈ $18.65K	ILA-21.37 Million ≈ $-57.30K	-3.072x	-241.08%
2023-12-31	ILA29.30 Million ≈ $78.57K	ILA-26.40 Million ≈ $-70.77K	-0.901x	-76.27%
2022-12-31	ILA56.39 Million ≈ $151.18K	ILA-28.82 Million ≈ $-77.25K	-0.511x	-8.30%
2021-12-31	ILA84.43 Million ≈ $226.35K	ILA-39.84 Million ≈ $-106.81K	-0.472x	+8.05%
2020-12-31	ILA30.68 Million ≈ $82.26K	ILA-15.75 Million ≈ $-42.21K	-0.513x	-153.70%
2019-12-31	ILA-13.72 Million ≈ $-36.79K	ILA-13.11 Million ≈ $-35.16K	0.956x	-77.39%
2018-12-31	ILA-3.18 Million ≈ $-8.52K	ILA-13.43 Million ≈ $-36.00K	4.226x	+128.21%
2017-12-31	ILA-6.38 Million ≈ $-17.12K	ILA-11.82 Million ≈ $-31.70K	1.852x	+41.67%
2016-12-31	ILA-7.36 Million ≈ $-19.74K	ILA-9.62 Million ≈ $-25.80K	1.307x	-77.50%
2015-12-31	ILA-1.39 Million ≈ $-3.72K	ILA-8.07 Million ≈ $-21.63K	5.809x	+144.38%
2014-12-31	ILA604.00K ≈ $1.62K	ILA-7.91 Million ≈ $-21.20K	-13.091x	-1005.65%
2013-12-31	ILA6.45 Million ≈ $17.28K	ILA-7.63 Million ≈ $-20.46K	-1.184x	+8.53%
2012-12-31	ILA7.47 Million ≈ $20.03K	ILA-9.67 Million ≈ $-25.93K	-1.294x	-132.19%
2011-12-31	ILA-881.00K ≈ $-2.36K	ILA-3.54 Million ≈ $-9.50K	4.022x	+7812.81%
2010-12-31	ILA-38.19 Million ≈ $-102.39K	ILA-1.94 Million ≈ $-5.20K	0.051x	-63.07%
2009-12-31	ILA-9.38 Million ≈ $-25.15K	ILA-1.29 Million ≈ $-3.46K	0.138x	-92.04%
2008-12-31	ILA11.86 Million ≈ $31.81K	ILA20.52 Million ≈ $55.01K	1.730x	--

About Bonus Biogroup

TA:BONS Israel Biotechnology

Market Cap

$129.94 Million

ILA48.47 Billion ILA

Market Cap Rank

#18205 Global

#234 in Israel

Share Price

ILA41.50

Change (1 day)

+0.48%

52-Week Range

ILA19.50 - ILA58.50

All Time High

ILA171.00